Biotech's blue shift

The biotech downdraft is having an ugly side effect outside of losing investors a lot of money: It's drastically reducing the number of "investable" biotech companies.

Wall Street typically considers any company with a market capitalization of less than $1 billion to be small cap, and many mutual funds have charters that keep them out of that space. As biotech valuations accelerated during the red shift of the genomics bubble,

Read the full 701 word article

How to gain access

Continue reading with a
two-week free trial.